HIMS FY2025 Q3 Revenue Increased by 49.2% Year-over-Year

Key Metrics

Executive Summary

Hims & Hers Health Inc. reported robust revenue growth of 49.2% in the third quarter of fiscal year 2025 compared to the same period last year, driven primarily by increased online sales and expanded product offerings. Despite significant top-line expansion, net income declined sharply by 79.2%, primarily due to increased operating expenses, marketing investments, and higher stock-based compensation. The company’s gross profit margin improved, reflecting better cost management and higher-margin product sales. Operating cash flow also increased by 44.9%, indicating strong cash generation from core operations, supporting ongoing investments and debt management.

Management Discussion and Analysis

The company’s revenue growth is attributable to a 49.2% increase in online sales, reaching nearly $599 million, supported by strategic acquisitions such as Zava and MedisourceRx, which contributed to top-line expansion. The gross profit margin improved from approximately 79.2% to 73.8%, reflecting favorable product mix and cost efficiencies. Operating expenses rose significantly, notably in marketing and technology development, to support customer acquisition and platform enhancements. The net income decline is mainly due to elevated operating costs, including a substantial increase in stock-based compensation expenses, which totaled over $100 million for the nine months. Cash flow from operations remains strong, bolstered by efficient working capital management and increased receivables collection.

Income Statement Analysis

Revenue increased by 49.2% YoY, from $401.6 million to $599 million, driven by growth in both direct-to-consumer and wholesale channels. Gross profit rose by 39.2%, with gross margin expanding due to improved cost controls. Operating expenses surged, especially in marketing (+27.4%) and technology (+24.0%), reflecting ongoing investments in platform scalability and customer engagement. Operating income declined from $22.4 million to $11.8 million, indicating margin compression amid higher expenses. Net income fell from $75.6 million to $15.8 million, with EPS decreasing correspondingly, highlighting the impact of increased operating costs and stock-based compensation on profitability.

Balance Sheet Analysis

Cash and cash equivalents increased by 56.7%, from $220.6 million to $345.8 million, supported by strong operating cash flow. Accounts receivable grew by 44.4%, reflecting higher sales volume, while inventory increased by 64.2%, indicating inventory build-up for upcoming product launches. Total assets surged to approximately $2.23 billion, mainly due to investments, goodwill, and intangible assets acquired through recent acquisitions. Total liabilities decreased slightly, with long-term debt remaining stable at $971 million, and total stockholders’ equity increased to $581 million, driven by retained earnings and additional paid-in capital.

Cash Flow Analysis

Operating activities generated $238.7 million, up 44.9% YoY, primarily from net income adjustments and working capital improvements. Investing activities used $941.3 million, mainly for acquisitions, capital expenditures, and investments in technology infrastructure. Financing activities provided $827.1 million, mainly from debt issuance related to convertible notes and stock issuance, offset by share repurchases totaling $9.5 million. Capital expenditures increased to support manufacturing and platform development, while debt management remains disciplined with no short-term borrowings as of the reporting date.

Ratios & DuPont Analysis

Net profit margin declined sharply to 2.6% from 18.8% YoY, mainly due to increased expenses. Return on assets (ROA) improved slightly to 0.7% from 0.4%, driven by higher asset base and cash flow. Return on equity (ROE) decreased significantly to 2.9% from 21.1%, impacted by net income decline and increased equity base. Asset turnover remained stable at approximately 0.27, indicating efficient utilization of assets. The equity multiplier increased to 3.84, reflecting higher leverage from debt issuance. Overall, the DuPont analysis shows margin compression amid higher expenses but stable asset efficiency.

Risk Factors

Hims & Hers faces regulatory risks related to healthcare compliance and data privacy, competitive pressures from other telehealth providers, operational risks from rapid scaling, and macroeconomic uncertainties affecting consumer spending. Market risks include fluctuations in reimbursement rates and insurance coverage. Financial risks involve debt management and stock-based compensation dilution. The company’s growth strategy depends on successful acquisitions and platform innovation, which carry integration and execution risks. External factors such as regulatory changes and economic downturns could impact future performance.

Notes & Additional Commentary

The decline in net income is primarily due to increased operating expenses, notably stock-based compensation and marketing investments. The company’s acquisitions of Zava and MedisourceRx contributed to asset and goodwill growth, with goodwill totaling approximately $259 million. Unusual items include a significant increase in stock-based compensation expenses, which are non-cash but impact profitability metrics. The company continues to invest heavily in platform development and customer acquisition, which may pressure margins in the short term but support long-term growth.

Investment Implications

Investors should consider the company’s strong revenue growth and cash generation as positives, but remain cautious about margin compression and high operating costs. The strategic acquisitions expand market reach and product offerings, supporting future growth potential. However, elevated expenses and net income volatility suggest a need for careful monitoring of cost controls and profitability trends. The company’s debt profile remains manageable, and its investment in platform scalability positions it well for long-term competitive advantage. A balanced approach is recommended, focusing on growth opportunities while managing operational risks.